Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Mizuho

Mizuho cut shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) from a buy rating to a neutral rating in a research report released on Thursday morning, reports. ARQT has been the subject of a number of other reports. TD Cowen lowered their price target on Arcutis Biotherapeutics from $65.00 to $50.00 and set an […]

Leave a Reply

Your email address will not be published.

Previous post Parex Resources (TSE:PXT) Price Target Increased to C$34.00 by Analysts at Canaccord Genuity Group
Next post Nomad Foods (NYSE:NOMD) Upgraded to Buy at